Solara Active Pharma Sciences shares jumped 5% on the NSE following the company's impressive Q1 FY2026 financial performance. The company delivered a consolidated net profit of ₹16.31 crore for the quarter ended June 30, 2026, representing a 55% year-on-year increase from ₹10.5 crore in the corresponding quarter of the previous year. According to the latest exchange filing, this significant profit growth was driven by higher revenue and operational efficiency during the quarter. The Board of Directors met on July 23, 2026, to review and approve the unaudited standalone and consolidated results for the quarter ended June 30, 2026. The strong performance comes as part of a broader earnings season with 63 companies announcing results today, including major names like Infosys, Cipla, and Indigo Airlines.
The company's revenue from operations increased 19.7% to ₹382 crore in Q1 FY2026, up from ₹319 crore in the same period last year. As reported in the latest filing, Managing Director and CEO Sandeep Rao highlighted that the base business reported revenue of ₹307.7 crore, up 24% year-on-year, demonstrating robust momentum supported by consistent operational execution and focus on profitable growth. The base business also showed strong operational metrics with gross margins rising 10% to ₹158 crore and EBITDA increasing 8% to ₹72.2 crore, despite higher raw material costs linked to geopolitical developments in West Asia. This performance builds on the company's recovery trajectory, having posted a consolidated net profit of ₹9.60 crore in Q4 FY6 after recovering from a net loss of ₹2.10 crore in Q4 FY5.
The company's EBITDA increased 8.6% year-on-year to ₹61.9 crore from ₹57 crore, though the EBITDA margin declined to 16.24% from 17.87% a year ago, reflecting the impact of higher input costs from ongoing geopolitical developments in West Asia. Despite these margin pressures, the company demonstrated strong financial discipline by reducing net debt by ₹134.6 crore during the quarter to ₹479.5 crore, bringing its annualised net debt-to-EBITDA ratio to around 1.9 times. CEO Sandeep Rao emphasized the company's focus on driving sustainable growth, improving margins and strengthening its balance sheet through disciplined execution and prudent capital allocation. The company has also scheduled an investor call at 4:00 PM IST on July 23, 2026, to address key operational trends and performance during the quarter.
The company's commodity Ibuprofen business continued to weigh on profitability, reporting another quarter of low gross margins and negative EBITDA margin of -12% amid a difficult operating environment. According to the latest filing, management is working with appointed bankers to evaluate strategic options for the business and expects to finalise the next steps by the end of the second quarter of FY27. The Ibuprofen business challenges have also impacted the proposed carve-out of the company's polymers and CRAMS businesses, which has been put on hold until strategic decisions regarding the Ibuprofen business are completed during the first half of FY27. The persistent weakness and pricing pressure in the commodity Ibuprofen segment continue to challenge consolidated margins, with management focusing on overcoming these headwinds to support the company's turnaround strategy.
